RioDerm-003 by Rion for Radiodermatitis: Likelihood of Approval

RioDerm-003 is under clinical development by Rion and currently in Phase I for Radiodermatitis.

Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C. – Biotech Investments

Issuer: Mainz BioMed N.V. / Key word(s): Conference 07.05.2024 / 14:01 CET/CEST The issuer is solely responsible for the content of this announcement. Mainz Biomed

May 8, 2024

Medtronic isn’t afraid of Wegovy’s potential to disrupt

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here

November 22, 2023

U.S. judge orders Minnesota to pause its drug pricing transparency law over constitutional issues

In a victory for the pharmaceutical industry, a U.S. judge ruled that Minnesota must temporarily halt a controversial law that is designed to provide transparency

December 6, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.